Statistics

Total Visits

Views
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)89

Select a period of time:

Number of views in the range

Views
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)14

Views

Views
September 20250
October 20252
November 20257
December 20252
January 20260
February 20261
March 20262
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil4
United States3
Argentina1
Chile1
Colombia1
Ecuador1
United Kingdom1
Uruguay1
 

Top cities views

Views
Ashburn2
Alvorada do Norte1
Guarulhos1
José C. Paz1
Montevideo1
Quito1
San Felipe1
São Francisco de Itabapoana1